Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245210 | 0.80 | LMNA (0.47) | LMNAGAAPOLBNPSR1L3MBTL1 | |
| SCHEMBL1746338 | 0.74 | — | — | |
| SCHEMBL28361930 | 0.73 | KDM4E (0.38) | LMNAGAAPOLBNPSR1L3MBTL1 | |
| SCHEMBL18704897 | 0.72 | CHRNA7 (0.39) | LMNAGAA | |
| SCHEMBL8659738 | 0.71 | KDM4E (0.42) | LMNAGAAPOLBNPSR1L3MBTL1 | |
| SCHEMBL18712982 | 0.70 | MC4R (0.39) | GAA | |
| SCHEMBL28326239 | 0.67 | CA1 (0.32) | POLBKMT2A | |
| SCHEMBL2778744 | 0.67 | POLB (0.43) | LMNAPOLBNPSR1L3MBTL1MEN1 | |
| SCHEMBL15014381 | 0.67 | SMN1; SMN2 (0.52) | GAAMEN1KMT2A | |
| SCHEMBL131930 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054414-A1 | DELIVERY ACROSS CELL PLASMA MEMBRANES | AVECTAS LIMITED (IE) | 2021-02-25 | — | — | US | claimed |
| US-20190194691-A1 | Vector-Free Delivery of Gene Editing Proteins and Compositions to Cells and Tissues | AVECTAS LIMITED (IE) | 2019-06-27 | — | — | US | claimed |
| US-10201499-B2 | Nanoparticle formulation | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2019-02-12 | — | — | US | claimed |
| EP-3397760-A2 | VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES | Avectas Limited (IE) | 2018-11-07 | — | — | EP | claimed |
| US-20170356011-A1 | Delivery Across Cell Plasma Membranes | AVECTAS LIMITED (IE) | 2017-12-14 | — | — | US | claimed |
| EP-3209303-A1 | DELIVERY ACROSS CELL PLASMA MEMBRANES | Avectas Limited (IE) | 2017-08-30 | — | — | EP | claimed |
| WO-2017115128-A2 | VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES | AVECTAS LIMITED (IE) | 2017-07-06 | — | — | WO | claimed |
| US-11981915-B2 | Vector-free intracellular delivery by reversible permeabilization | AVECTAS LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| US-20240110144-A1 | DELIVERY PLATFORM | AVECTAS LIMITED (IE) | 2024-04-04 | — | — | US | disclosed |
| EP-4284910-A1 | DELIVERY PLATFORM | Avectas Limited (IE) | 2023-12-06 | — | — | EP | disclosed |
| US-11827899-B2 | Vector-free delivery of gene editing proteins and compositions to cells and tissues | AVECTAS LIMITED (IE) | 2023-11-28 | — | — | US | disclosed |
| US-11332757-B2 | Delivery across cell plasma membranes | AVECTAS LIMITED (IE) | 2022-05-17 | — | — | US | disclosed |
| EP-3559204-B1 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | AVECTAS LTD (IE) | 2022-05-04 | — | — | EP | disclosed |
| US-20200063162-A1 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | AVECTAS LIMITED (IE) | 2020-02-27 | — | — | US | disclosed |
| EP-3559204-A2 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | Avectas Limited (IE) | 2019-10-30 | — | — | EP | disclosed |
| US-20190194691-A1 | Vector-Free Delivery of Gene Editing Proteins and Compositions to Cells and Tissues | AVECTAS LIMITED (IE) | 2019-06-27 | — | — | US | disclosed |
| EP-3397760-A2 | VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES | Avectas Limited (IE) | 2018-11-07 | — | — | EP | disclosed |
| US-20170356011-A1 | Delivery Across Cell Plasma Membranes | AVECTAS LIMITED (IE) | 2017-12-14 | — | — | US | disclosed |
| EP-3209303-A1 | DELIVERY ACROSS CELL PLASMA MEMBRANES | Avectas Limited (IE) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017115128-A2 | VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES | AVECTAS LIMITED (IE) | 2017-07-06 | — | — | WO | disclosed |